Skip to content
★ Sign in to follow
BH

Broncus Holding Corporation - B Stock: price and insider trades · Hong Kong

HK·Mcap HK$337.3MHealth Care

No insider purchase over the last 90 days. The latest, by KUANG Yanhong, was filed 10 Apr 2025.

Broncus Holding Corporation - B: what insiders have been doing

This page follows insider dealings at Broncus Holding Corporation - B as filed with HKEX, a company from the Health Care sector. Broncus Holding Corporation - B has had no insider filing for more than a year; the last one goes back to 23 July 2025.

The full history, which starts in 2021, counts 14 purchases against 4 sales.

In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.

Insider Decl.
18
Thresholds
n/a
Buy Volume
€93,115
14 ops. · all time
Sell Volume
n/a
4 ops. · all time

Who traded when

BuySale
KUANG Yanhong1 buy1 sale

Since the insiders bought

  • Filed 10 Apr 2025 · 577 days ago · €7,259
    +33.0%
    Entry HK$1.03 · Close at T+365 HK$1.37
  • Filed 20 Dec 2021 · 1784 days ago · €458
    -72.2%
    Entry HK$8.20 · Close at T+365 HK$2.28
  • Filed 17 Dec 2021 · 1787 days ago · €22k
    -71.2%
    Entry HK$8.36 · Close at T+365 HK$2.41

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 18,557 of 26,914 companies
38.9
score / 100
Value
25
Quality
53
FCF yld-3.1%
Earn yld-4.5%
EV/EBITDA·
ROE-12%
Gross mgn76%
Net mgn·
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2024

FY ended December 2024 · cache

HK$0.64
Analyst consensus
·
Income statement
RevenueHK$8.1M
Gross profitHK$6.1M76% margin
EBITDA-HK$12M-148% margin
Net income-HK$15.3M-188.2% margin
Valuation
P/Book0.3x
Beta1.11
Balance sheet & cash
Market capHK$337.3M
Total debtHK$318k
Free Cash Flow-HK$10.3M
Debt / Equity0%
Profitability & ownership
ROE-12.0%
ROA-8.7%
% insiders8.9%
% institutions29.1%
Last declaration on 23 July 2025
Declarations18 total
  • ▼
    DirectorExecutives
    0HKEX
    1,900,848 sharesShareXHKGHKEX:DA20250723E00414
  • ▲
    DirectorExecutives
    61,560 HKD18HKEX
    76,000 shares@ HK$0.8171.5% of flowShareXHKGHKEX:DA20250410E00031
    Canonical exit: 6 Jul 2025 (T+90)
  • ▲
    DirectorExecutives
    4,700 HKD12HKEX
    10,000 shares@ HK$0.475.6% of flowShareXHKGHKEX:DA20241120E00197
    Canonical exit: 12 Feb 2025 (T+90)
  • ▲
    DirectorExecutives
    7,440 HKD12HKEX
    15,500 shares@ HK$0.488.7% of flowShareXHKGHKEX:DA20241120E00196
    Canonical exit: 6 Feb 2025 (T+90)
  • ▲
    DirectorExecutives
    5,445 HKD12HKEX
    11,000 shares@ HK$0.4956.4% of flowShareXHKGHKEX:DA20241120E00195
    Canonical exit: 5 Feb 2025 (T+90)
  • ▲
    DirectorExecutives
    2,640 HKD11HKEX
    5,500 shares@ HK$0.483.1% of flowShareXHKGHKEX:DA20241120E00194
    Canonical exit: 4 Feb 2025 (T+90)
  • ▲
    DirectorExecutives
    3,960 HKD11HKEX
    8,000 shares@ HK$0.4954.6% of flowShareXHKGHKEX:DA20241120E00193
    Canonical exit: 16 Jan 2025 (T+90)
  • ▼
    DirectorExecutives
    0HKEX
    6,816,641 sharesShareXHKGHKEX:DA20240207E00330
  • ▼
    DirectorExecutives
    0HKEX
    919,975 sharesShareXHKGHKEX:DA20240207E00329
  • ▲
    DirectorExecutives
    0HKEX
    162,947 sharesShareXHKGHKEX:DA20240207E00328
    Canonical exit: 16 Apr 2024 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    144,129 sharesShareXHKGHKEX:DA20240207E00327
    Canonical exit: 16 Apr 2024 (T+90)
  • ▼
    DirectorExecutives
    0HKEX
    21,956,727 sharesShareXHKGHKEX:DA20231122E00378
  • ▲
    DirectorExecutives
    0HKEX
    919,975 sharesShareXHKGHKEX:DA20231122E00376
    Canonical exit: 15 Feb 2024 (T+90)
  • ▲
    DirectorExecutives
    4,040 HKD23HKEX
    500 shares@ HK$8.081.0% of flowShareXHKGHKEX:DA20211220E00365
    Canonical exit: 16 Mar 2022 (T+90)
  • ▲
    DirectorExecutives
    196,295 HKD17HKEX
    21,500 shares@ HK$9.1358.5% of flowShareXHKGHKEX:DA20211217E00062
    Canonical exit: 14 Mar 2022 (T+90)
  • ▲
    DirectorExecutives
    390,080 HKD31HKEX
    46,000 shares@ HK$8.4899.0% of flowShareXHKGHKEX:DA20211216E00075
    Canonical exit: 15 Mar 2022 (T+90)
  • ▲
    DirectorExecutives
    92,140 HKD14HKEX
    10,000 shares@ HK$9.21427.4% of flowShareXHKGHKEX:DA20211215E00052
    Canonical exit: 13 Mar 2022 (T+90)
  • ▲
    DirectorExecutives
    47,225 HKD12HKEX
    5,000 shares@ HK$9.44514.1% of flowShareXHKGHKEX:DA20211213E00266
    Canonical exit: 10 Mar 2022 (T+90)

18 of 18 declarations

About Broncus Holding Corporation - B

Broncus Holding Corporation - B is a company listed on the Hong Kong Stock Exchange, specializing in the development of medical solutions for the treatment of lung diseases. It focuses on innovation in medical devices and health technologies.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations